Alnylam Files for Initial Public Offering | GenomeWeb

NEW YORK, March 1 (GenomeWeb News) - Alnylam Pharmaceuticals has filed a statement with the SEC for an initial public offering, the company said Friday evening.

 

The number of shares of common stock Alnylam plans to offer, and their price, have yet to be determined. Bank of America Securities serves as the company's book-runner and lead manager.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.